Key result
A high preoperative neutrophil-to-lymphocyte ratio (≥3.8) was an independent risk factor for shorter progression-free survival in patients with HCC undergoing interventional therapies (P<0.05).
Why the study?
This study aimed to examine the prognostic value of blood neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma.
Does a high preoperative neutrophil-to-lymphocyte ratio predict poor overall and progression-free survival in patients with hepatocellular carcinoma undergoing interventional therapies?
Cohort (n=543)
Does a high preoperative neutrophil-to-lymphocyte ratio predict poor overall and progression-free survival in patients with hepatocellular carcinoma undergoing interventional therapies?
p-value: p=< 0.05
An elevated preoperative neutrophil-to-lymphocyte ratio (≥3.8) is an independent predictor of poor progression-free survival in patients with hepatocellular carcinoma undergoing interventional therapies.
May inform preoperative risk stratification in HCC; leaves open need for prospective validation before guiding therapy.
This study is aimed at examining the prognostic value of blood neutrophil‐to‐lymphocyte ratio (NLR) in patients with hepatocellular carcinoma (HCC). Demographic and clinical data of 543 HCC patients treated with interventional therapies were retrospectively analyzed. Preoperative NLRs were determined and receiver operating characteristic (ROC) curves were plotted for survival time in patients with high (NLR ≥3.8) and low (NLR<3.8) NLR. The median overall survival (OS) was 1241 days after interventional therapies and was significantly reduced in the high NLR group when compared to the low NLR group. The median progression‐free survival time (PFST) of patients was also significantly shorter in the high NLR group than in the low NLR group. Univariate analysis revealed that tumor type, therapy method, maximum tumor size (>3 mm), and NLR (>3.8) were risk factors for OST and PFST (P < 0.05). Multivariate analysis indicated that tumor type, maximum tumor diameter, therapy method, and NLR (>3.8) were independent risk factors for PFST (P < 0.05). Our results demonstrate that preoperative NLR has prognostic value for patients with HCC undergoing interventional therapies, and high NLR is an indication of poor prognosis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted a cohort in Hepatocellular carcinoma (n=543). High neutrophil-to-lymphocyte ratio (NLR ≥3.8) vs. Low neutrophil-to-lymphocyte ratio (NLR <3.8) was evaluated on Overall survival and progression-free survival time (p=< 0.05). A high preoperative neutrophil-to-lymphocyte ratio (≥3.8) was an independent risk factor for shorter progression-free survival in patients with HCC undergoing interventional therapies (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: